Impax Labs Shares Down Sharply After FDA CRL for RYTARY NDA; Canaccord Says Buy the Dip

By: Benzinga
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL ), announced early Sunday the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for RYTARY™ (IPX066), an extended-release capsule formulation of carbidopa-levodopa, a potential treatment for the symptomatic treatment of Parkinson's disease currently under review
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.